Cai Grau

Danish Centre for Particle Therapy

Cai Grau is Professor of Radiation Oncology at the Institute of Clinical Medicine at Aarhus University and heading the interdisciplinary radiotherapy research at the Department of Oncology and the Danish Center for Particle Therapy at Aarhus University Hospital in Aarhus, Denmark. He is chairman of the Scientific Committee of the Danish Comprehensive Cancer Center (DCCC.dk) and director of the national research center DCCC Radiotherapy (DCCCRT.dk). His main area of interest is research in head and neck oncology, high precision radiotherapy, proton therapy, and health economics in radiation oncology.

Professor Grau is active in several national and international research collaborative groups, including the Danish Head and Neck Cancer Group (DAHANCA), and coordinator of the European Particle Therapy Network (EPTN).

He has been the supervisor of more than 20 Ph.D. and DMSc projects within radiotherapy, particle therapy, medical physics, clinical oncology. He has published more than 200 scientific publications.

Eric Chang

USC Norris Cancer Hospital,Keck Hospital of USC

Dr. Chang uses advanced radiation therapy techniques to treat a variety of benign and malignant brain tumors, and spine tumors. He is considered a world authority in the use of radiation therapy in the treatment of benign conditions and malignant tumors of the central nervous system, and is highly experienced in handling both routine cases, and the most complex cases requiring radiotherapeutic evaluation in a multi-disciplinary setting of experts comprising neuro-radiation oncologists, neurosurgeons and neuro-oncologists, and neuro-radiologists.

Dr. Chang received his undergraduate degree in Biology from the Massachusetts Institute of Technology and medical doctorate degree from Harvard Medical School. His internship in medicine was performed at the California Pacific Medical Center and residency training was conducted at the Harvard Joint Center for Radiation Therapy, in Boston, Massachusetts. He has held research leadership roles including having served as member and Chair of the M. D. Anderson Cancer Center Clinical Research Committee (CRC). He was the 2011 CNS track leader for the American Society for Clinical Oncology (ASCO) Scientific Program Committee, and member of the ASCO Cancer Education Committee. Dr. Chang has served as the co-leader for the American Society of Radiation Oncology (ASTRO) brain metastasis guidelines development task force and member of the Annual Program Committee of the Educational Council of ASTRO. He is the current chair of the American Radium Society Brain Appropriate Use Committee. He has been listed in the Best Doctors 2019-2020 Directory. Dr. Chang led a phase III randomized controlled trial on brain metastasis published in the Lancet Oncology 2009 which has changed the practice patterns for metastatic brain disease. Dr. Chang has been selected as a plenary speaker for past meetings of ASTRO and the American Association for Neurological Surgeons (AANS). He has authored or co-authored over 100 peer-reviewed papers and abstracts.

In addition to serving as Chair of the Department of Radiation Oncology at Keck Medicine of USC, Dr. Chang also serves as the Medical Director of the Radiation Oncology Service at Children's Hospital Los Angeles, and Medical Director of St. Jude Medical Center Radiation Oncology Department in Fullerton, CA.

Yolande Lievens

Ghent University Hospital

Prof. Dr. Yolande Lievens is the current chair of the radiation oncology department of the Ghent University Hospital inGhent, Belgium, and associate professor at the Ghent University. She graduated from theCatholic University in Leuven, where she acquired her degrees in Medicine, Radiation Oncologyand Hospital and Health Care Management, and completed her PhD in cost accounting andeconomic evaluation of radiotherapy.

Her clinical focus lies on radiation therapy for thoracic malignancies, with an additional interest forthe role of radiotherapy in hematology and breast cancer. She is closely involved in the organizational aspects of radiotherapy, the position ofradiotherapy in multidisciplinary oncology and the financial and health economic aspects ofcancer care, in Europe and worldwide. She is interested in quality issues related to radiationoncology, in terms of quality assurance as well as the impact of radiation treatments on quality-of-life.

She is former president of ESTRO and ofthe Belgian College for Physicians inRadiation Oncology. She is, a.o.,(co-)steering the Health Economics in Radiation Oncology(ESTRO-HERO),Global Impact of Radiotherapy in Oncology (ESTRO-GIRO)andE2-RADIATE(EORTC-ESTRO Infrastructure for Radiotherapy in Europe) projects, as well as the Treatment Optimizationand Health Systems Network of the European Cancer Organization.

She is convinced that an optimal combination of clinical, translational and health services research is key to the future of radiation oncology and toadvance the outcome of cancer patients, by sustaining innovation in and access toradiotherapy in a multidisciplinary oncology environment.

Rakesh Jalali

Apollo Proton Cancer Centre, Chennai, INDIA

Professor Rakesh Jalali is the Medical Director of India’s and South Asia’s first proton therapy facilityApollo Proton Cancer Centre leading its clinical care administration.

Prof. Jalali is widely recognized globally for his contributions in neuro-oncology,particularly for high-precision radiotherapy and enhancing quality of life for cancer patientsalong withvarious other aspects of cancer care. It is to his credit and foresight that the ‘Neuro Oncology’ Group at TMH, which he developed, is hailed as the finest such unit in India and recognized throughout the world.

He was also instrumental in establishing the Indian Society of Neuro-Oncology (ISNO) in 2008 serving as its founding general secretary, then its President and now chairing its senior advisory council.He has led and mentored various cancer initiatives globally including in Asia-Pacific and African regions. Prof Jalali’s numerous research publications including in high-impact journals such as the Lancet, Lancet Oncology, JAMA Oncology, JCO, etc; have been helpful in guiding treatment philosophies in the management of cancers. A much sought after speaker, he is widely regarded for his teaching and providing expert guidance to various national and international scientific meetings and professional societies. Prof Jalali is also well-known for his commitment to promoting equitable cancer care for patient populations from diverse backgrounds. He was instrumental in shaping upthe ‘Brain Tumour Foundation of India’, an internationally recognized charity dedicated to the welfare of the patients with brain tumours and their families, as well as conducting ‘Patient support group’ meetings for cancer patients and their caregivers.

Philippe Lambin

Head of the Department of Precision Medicine, Maastricht University, The Netherlands

LAMBIN Philippe: Doctor of Medicine (MD), Université Catholique de Louvain, Belgium Doctor of Sciences (Ph.D.), Specialist in Radiation-Oncology, Professor& Head of the Department of Precision Medicine, The D-Lab & The MLab, University of Maastricht the Netherlands, Scientist at the Institute Bordet & Université Libre de Brussels (ULB), academic entrepreneur Status: Married, four children - three stepchildren (20 years old – 30 years).

Philippe Lambin is a Clinician, Radiation Oncologist, “ERC advanced & twice ERC PoC grant laureate” respectively from 2016, 2017 & 2020 and pioneer in translational research with a focus on tumor hypoxia and Decision Support Systems. He has a PhD in Molecular Radiation Biology and is Professor at the University of Maastricht (Radiation Oncology) and at the University of Eindhoven (“Functional Imaging”, until 2011). He is co-author of more than 523 peer reviewed scientific papers (Hirsch Index: 100 Google scholar), co-inventor of more than 20 patent families (filed or submitted) of which 8 are in the (pre)commercialization phase and (co) promoter of more than 60 completed PhD’s (2 with cum laude). Moreover, Prof. P. Lambin has extensive experience with clinical trials. He has been one of the international experts in the flims workshop “Methods in Clinical Cancer Research organized jointly by the FECS, AACR and ASCO and he is leading several clinical trials (see www.clinicaltrials.gov: his name is mentioned as Principal Investigator in 30 clinical trials). He has been also a member of the scientific committee of KWF (the main Dutch funding body in cancer research) and of the advice committee on protontherapy of CVZ (the Dutch medical insurance). He is currently involved in several successful European grants (e.g. CDPT, Biocare, Euroxy, Metoxia, Eureca, Artforce, Radiate, Quick-Concept, Requite, BD2decide, SCANnTREAT, EuCanImage, CHAIMELEON, DRAGON, iCOVID, AUTO.DISTINCT, LIVINGVAC…) including ImmunoSABR (6 millions €, a Multicentric randomized trial in metastatic lung cancer comparing radiotherapy plus or minus immunotherapy) and the Marie Curie Training network PREDICT of which he is the initiator and the coordinator and two NIH grant (“Radiomics”) form the US. His main areas of interest are directed towards translational research in tumour Biology with a specific focus on tumour hypoxia, functional imaging (Radiomics), lung and head and neck cancer. More recently, his interests have been directed towards hypoxia targeting, Hypoxia Activated Prodrugs, during immunotherapy, genetically modified bacteria as living medicine and the development of “AI-based treatment decision support system” based on multi parametric databases containing clinical, imaging, biological and therapeutic information, and taking into account patient preferences. The website he launched, predictcancer.org, with validated predictive models has had more than 20.000 visitors from more than 133 countries. He is one of the inventors of “Radiomics” (watch the animation), “Clinical Decision Support Systems” (animation), “Distributed learning” a revolutionary Big Data approach for health care (watch the animation of a project he managed), use of genetically modified bacteria (animation) and the combination of immunocytokines with radiation (animation). Few years ago, his research group received the highest possible score (‘excellent’ – 5 - on all aspects) by an international external review committee and was described as having a “World leading position”. The reviewers added, “In large part, this is due to the inspirational leadership of Prof. P. Lambin who has done an outstanding job of building a world-class research program within a relatively short period of time”. He is also a serial entrepreneur, founder and/or non-executive advisor, without decision making power of: Oncoradiomics, Convert Pharmaceuticals, MedC2, Exomnis, Living Med Biotech, DNAmito/ptTheragnostic, Medneon.

Debbie Gilley

International Atomic Energy Agency

Debbie is a Radiation Protection Specialist with the International Atomic Energy Agency in the Division of Radiation, Transport and Waste Safety Radiation Protection of Patients Unit. Her activities within the Agency included the development and implementation of the Safety in Radiation Oncology medical event reporting system (SAFRON), assisting in IAEA patient protection and safety campaigns and assisting countries in supporting radiation protections of patient activities. She is a contributing author of several IAEA publications on patient safety and a chapter in the recently published book entitled “Modern Technology of Radiation Oncology” and Radiotherapy in Cancer Care: Facing the Global Challenge”. Past professional responsibilities include Government Relations Specialist with the American Association of Physicists in Medicine (AAPM) where she supports the Association in areas for state government relations and patient safety in imaging and therapy physics. Twenty-four years of service to the Florida Bureau of Radiation Control, United States as Manager of the Training and Quality Assurance Program, Manager of the Radioactive Materials Program, and investigator for reported radiological medical events. Academically she has an undergraduate and master’s degree from Florida State University and has also attended Oak Ridge Associated Universities. She served as the agreement state representative to the US NRC Advisory Council on the Medical Use of Isotopes (ACMUI) from 2008 until 2011. She is a past board member and chairperson (2008) of the Conference of Radiation Control Program Directors (CRCPD). She is a Past President and Secretary of the Florida Chapter of the Health Physics Society (HPS) and member of several AAPM and HPS committees and a delegate to the International Radiation Protection Association.

Eduardo Zubizarreta

International Atomic Energy Agency - IAEA.

Training

Zubi specialised in radiation oncology in Bueanos Aires, Argentina, after obtaining his MD degree from the University of Buenos Aires in 1980. He moved to Uruguay in 1989, where he obtained the degree of Doctor in Medicine from the University of the Republic in 1990. In 1995 he was fellow at the Mallinckrodt Institute of Radiology, Washington University in St Louis, USA.

Main interests and Global collaborations / HE

After a career of 26 years as a radiation oncologist in Argentina and Uruguay zubi joined the IAEA in 2006. He has been responsible for 100 technical cooperation projects worldwide and for many technical publications, and has conducted several research projects. He collaborated with the GTFRCC and is actively engaged in several global health projects.

Short statement

As the gap in access to radiotherapy is so big in poor regions we need to be creative but at the same time realistic to choose interventions that can obtain the biggest impact with minimum effort. Global health initiatives like GIRO have a great opportunity to propose initiatives that can improve access to radiotherapy.

Mary Gospodarowicz

Princess Margaret Cancer Centre

Mary Gospodarowicz is University Professor at the University of Toronto, past Medical Director of Princess Margaret Cancer Centre/University Health Network, and past Regional Vice President of Cancer Care Ontario. She is a Past-President of the Union for International Cancer Control (UICC). Her research focused on clinical trials evaluating radiation therapy in GU cancers and lymphomas, image-guided precision radiotherapy, and cancer survivorship. Her current interests include prognosis and cancer staging, global cancer control, quality in cancer care, and mentorship.

She is a Fellow of the American Society in Radiation Oncology (ASTRO), Honorary Fellow of the UK Royal College of Radiologists, Honorary Fellow of the Faculty of Radiologists in the Royal College of Surgeons of Ireland, honorary member of the European Society of Radiation Oncology, as well as the German and Swiss radiation oncology societies. She is a recipient of the ASTRO Gold Medal, American Radium Society Janeway Medal, O. Harold Warwick Prize from Canadian Cancer Society, and the Women Who Conquer Cancer Mentorship Award from the American Society of Clinical Oncology. She was appointed Officer of the Order of Canada in 2015.

Currently she is engaged in the UICC TNM Prognostic Factors Project, City Cancer Challenge Foundation Board of Directors. At the Princess Margaret she is engaged in the Global Cancer Program, the Young Leaders and the Elders.

Minesh Mehta, M.D.

Miami Cancer Institute

Minesh Mehta, M.D., Deputy Director and Chief of Radiation Oncology at Miami Cancer Institute, is a world-renowned expert in proton therapy, radiosurgery, brain tumors, and cancer research. He oversees one of the most comprehensive radiation therapy programs, including South Florida’s first Proton Therapy Center and a comprehensive suite of the most sophisticated radiation treatment technologies.

Dr. Mehta came from the University of Maryland’s Proton Treatment Center, where he launched the mid-Atlantic’s first dedicated pencil-beam proton treatment center and served as its Medical Director.

Previously, he was the Chairman of the University of Wisconsin’s Department of Human Oncology, where he led numerous research studies, innovative technology development through federally-funded team science grants (Tomotherapy PO1), and oversaw substantial practice expansion. He was also Program Leader for the Comprehensive Cancer Center’s Imaging and Radiation Sciences Program (P30) for approximately 15 years, led a project grant (U01) in brain tumor clinical trials, and has been the Chair of the RTOG/NRG Oncology’s Brain Tumor Committee since 1999, funded by NIH CA RTOG and NRG grants.

Dr. Mehta has designed and led several national and international clinical studies, receiving NIH, NCI, and industry grants and been awarded many honors. He has held national leadership positions in almost two dozen organizations.

Dr. Mehta has over a thousand publications, including manuscripts, book chapters, and professional abstracts, and serves on the editorial board of several peer-reviewed journals.

Dr. Mehta graduated with honors from the University of Zambia School of Medicine and completed his residency at the University of Wisconsin.

Suresh Senan

Amsterdam University Medical Centers

Suresh Senan is Professor of Clinical Experimental Radiotherapy at the Amsterdam University Medical Centers, The Netherlands. He completed his training in clinical oncology in the United Kingdom. His recent research has focused on stereotactic radiotherapy, use of immune checkpoint inhibitors, and Magnetic Resonance-guided radiotherapy. He is an active member of the European Society for Medical Oncology, International Association for the Study of Lung Cancer and ASTRO.

Priyamvada Madan Maitre

Radiation Oncology

Designation: Assistant Professor, Dept of Radiation Oncology, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Mumbai

Career Vision: Increasing the accessibility of quality radiotherapy for genitourinary cancers
Winner of Dr. G.C. Pant Young Doctor Award and Fellowship at the 40th Annual AROICON 2018

Major publications:

  1. Late toxicities and quality of life with Prostate Only or Whole Pelvic Radiation Therapy in high risk prostate cancer (POP-RT): A Prospective Randomized Controlled Trial - Murthy V, Maitre P, Bhatia J, Kannan S, Krishnatry R, Prakash G, Mahantshetty U. Radiotherapy and Oncology (2020)
  2. Prostate only versus whole pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial – Murthy V, Maitre P, Kannan S, Panigrahi G, Krishnatry R, Bakshi G et al. Journal of Clinical Oncology (2021, In press)
  3. Adaptive Radiotherapy for Carcinoma of the Urinary Bladder: Long Term Outcomes with Dose Escalation - Murthy V, Gupta P, Baruah K, Krishnatry R, Joshi A, Prabhash K, et al. Clinical Oncology (2019)
  4. Prostate Radiotherapy in India: Evolution, Practice and Challenges in the 21st Century – Murthy V, Mallick I, Arunsingh M, Gupta P. Clinical Oncology (2019)
  5. 68Ga-PSMA PETCT Based Response to Androgen Deprivation Therapy in Patients with Prostate Cancer – Gupta P, Murthy V, Agarwal A, Maitre M, Mhatre N, Rangarajan V. Nuclear Medicine Communications (2019)

Ongoing projects:
  1. Combining urinary symptoms and cytology to decrease the need of cystoscopies at follow-up assessments after bladder preserving tri-modality treatment (TMT) in muscle invasive bladder cancer: A retrospective study (PI: Dr Rahul Krishnatry)
  2. Randomised controlled trial of Prostate Radiotherapy In high risk and node positive disease comparing Moderate and Extreme hypofractionation [PRIME Trial] (PI: Dr Vedang Murthy)
  3. Toxicity and outcomes in Gleason grade group 5 prostate cancer treated with radical radiotherapy: An Indian multi-institutional retrospective study (PI: Dr Vedang Murthy)

Jatinder Palta

Virginia Commonwealth University

Professor Palta is the Chairman of Medical Physics in the Department of Radiation Oncology at Virginia Commonwealth University and National Chief of Physics in the office of VHA National Radiation Oncology Program. Dr. Palta is internationally recognized for his clinical research and educational activities in advanced radiotherapy techniques, quality assessment, and quality assurance. He has distinguished himself by contributing significantly to the professions of radiation oncology and medical physics through funded research, inventions, over 250 journal articles and book chapters, teaching, clinical services, mentoring of younger colleagues, and outreach activities. He is a recipient of the William D. Coolidge Gold Medal from the American Association of Physicists in Medicine. This is the highest award given by the AAPM to an individual who has exhibited a distinguished and eminent career in medical physics, and who has exerted a significant impact on the practice of medical physics. Dr. Palta’s professional career is now focused on enhancing the quality and safety of radiotherapy. He is developing and implementing programs that will ensure safe, effective, state-of-the-art radiation treatment to US Veterans and bring Veterans Health Administration Radiation Oncology Services to a position of global excellence.

Arjun Sahgal

Sunnybrook Health Sciences Centre

Dr. Arjun Sahgalis an international clinical and research leader in the field of high precision stereotactic radiation to the brain and spinefor both metastases and primary tumors. After training at the University of Toronto in radiation oncology, he completed a radio surgery fellowship at the University of California San Francisco. He has published,as lead or as a contributor, over 500 peer reviewed papers including in high impact journals like the Journal of Clinical Oncology, Lancet Oncology, and New England Journal of Medicine. He leads the Sunnybrook Odette CNS Neuro-Oncology program that has been awarded a total of $42.5M in fundingsince his leadership. Currently, he serves as Deputy Chief of the Department of Radiation Oncology at the University of Toronto affiliated Sunnybrook Odette Cancer Centre. In addition, he is the director of the Sunnybrook Cancer Ablation Therapy(CAT)program which involved the installation of a MR Brachy therapy suite, MR Linac and Gamma Knife Icontechnology. His next phase of research is in the development of MR in radiation therapy, and the application of MR Guided Focused Ultrasound Technology with radiation. He recently showed in the SC24 randomized trial superiority of spine SBRT as compared to conventional radiation

Andre Dekker

Maastrict University

Prof. Andre Dekker, PhD (1974) is a medical physicist and professor of Clinical Data Science at Maastricht University Medical Center and Maastro Clinic in The Netherlands. His Clinical Data Science research group (30 staff) focuses on 1) federated FAIR data infrastructures, 2) AI for health outcome prediction models and 3) applying AI to improve lives of patients and citizens. Prof. Dekker has authored over 170 publications (h-index 55+), mentored more than 30 PhD students and holds multiple awards and patents on the topic of federated data and AI. He has held visiting scientist appointments at universities and companies in the UK, Australia, Italy, USA and Canada.

Sushil Beriwal

UPMC Hillman Cancer Center

• Professor, Radiation Oncology, and Director, Residency Program
• Deputy Director of Radiation Services, UPMC Cancer Center
• Medical Director, Department of Radiation Oncology, Magee-Womens Hospital of UPMC
• Director, Brachytherapy, University of Pittsburgh Cancer Center
• Associate Pathway Director

Dr. Beriwal is professor of radiation oncology at the University of Pittsburgh school medicine. He is specialize in gynecologic, breast, and prostate cancers, with an emphasis on high dose rate brachytherapy for cervix, uterine, vagina, and breast cancers, along with prostate seed implantation, image-guided radiation therapy, and intensity modulated radiation therapy. He is actively involved with clinical research with more than 175 peer reviewed publications. He is also ABR board examiner and on the editorial board of Brachytherapy and also senior editor for Red journal. He provides oversight and supervision of clinical radiation oncology at UPMC Magee and UPMC Mercy Hospital. He is actively involved in residency and medical student teaching and research as program director. His research interests are 3D image-based brachytherapy, IMRT and IGRT, outcome analysis for breast prostate and gynecological cancers, Clinical Pathways, and NCDB data analysis.

Teaching Activities

• Radiation Oncology Residents
• Mentor Residents in Research
• Fellows in Gynecologic Oncology: Provide didactic lecture to fellows at least once per academic year. One (or more) month rotation during three year fellowship
• Fellows in Surgical Oncology: One or more month rotation during fellowship
• Medical Students - Summer and/or longitudinal research

Education & Training

• R G Kar Medical College, Calcutta, India, MD
• Hahnemann/Drexel University College, Philadelphia, PA
• Arnold R Eiser, MD Internal Medicine Residency Pr, Darby, PA
• Post Graduate Institute of Medical Education & Research, Chandigarh, India

Bhisham Chera

University of North Carolina

Dr. Chera is an Assistant Professor and Director of Patient Safety and Quality in the Department of Radiation Oncology at the University of North Carolina. He received his B.S. in Biology from Winthrop University in 2000 and a M.D. from the Medical University of South Carolina in 2004. He completed his residency training in radiation oncology at the University of Florida. His clinical expertise is in head and neck and skin cancers. His major areas of research pertain to head and neck cancer and translating quality assurance/control/improvement principles and methodologies from high reliability organizations to radiation oncology. He has written on the incorporation of practical quality assurance approaches (e.g. process/human factors engineering and Lean methodologies) in the daily activities of radiation oncology departments/clinics.

Karyn Goodman

Mount Sinai Hospital

Karyn Aalami Goodman, MD, MS, joined Mount Sinai in September, 2019 as Professor and Vice Chair for Research and Quality in the Department of Radiation Oncology. She is also Associate Director for Clinical Research at The Tisch Cancer Institute. Dr. Goodman was most recently at the University of Colorado School of Medicine since 2015, where she served as Associate Director of Clinical Research for the University of Colorado Cancer Center. She was on the faculty at Memorial Sloan Kettering Cancer Center prior to that.

Dr. Goodman is an internationally recognized expert in gastrointestinal (GI) cancers and has served in numerous leadership roles on committees to establish national treatment guidelines and best practices for the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the American College of Radiology. She is involved in developing and leading clinical trial for novel approaches to GI cancers. Her research focuses on improving outcomes and reducing toxicity in patients with GI malignancies. She is involved in the development of therapeutic protocols combining radiation, chemotherapy, targeted agents, and immunotherapy for gastrointestinal cancers. Her experience as principal investigator on clinical trials is extensive, and she has received numerous grant awards. She is the national Radiation Oncology principal investigator of the RTOG/NRG 0848 study, a phase III trial evaluating the use of post-operative radiotherapy for pancreatic cancer and the national Study Chair for the recently completed CALGB/Alliance Cooperative Group phase II trial (CALGB 80803) investigating PET scan-directed therapy for esophageal cancer. She currently serves as the Co-Chair of the National Cancer Institute (NCI) Gastrointestinal Steering Committee where she helps to set the strategic priorities for the development of Phase II and III clinical trials in GI cancers conducted through the National Clinical Trials Network (NCTN).

Dr. Goodman received her undergraduate and medical degrees from Stanford University and an MS in Epidemiology from the Harvard School of Public Health. She completed an internship in Internal Medicine at Stanford and residency training at Memorial Sloan-Kettering Cancer Center. She was on the faculty at Stanford University from 2004-2006 and then was the head of Gastrointestinal Radiation Oncology at Memorial Sloan Kettering from 2007-2015. She has published over 200 peer-reviewed scientific articles, review articles, and chapters.

Shyam Shrivastava

Apollo Hospitals, Navi Mumbai

Dr Shyam Shrivastava, Director Radiation Oncology, at the Apollo Hospitals, Navi Mumbai, India.

He completed his MBBS & later post-graduation MD (Radiotherapy) from MGM Medical College, Indore in 1981. He is also obtained a degree “Diplomate of the National Board (DNB)”, New Delhi in 1984.

Dr. Shrivastava has over 35 years’ experience in the field of Radiation Oncology focusing on advances in the treatment in cancer, quality of life issues and global health. He joined Tata Memorial Hospital in 1982 & has been Head of the Department of Radiation Oncology for more than 12 years. He is actively involved in research and has played a pivotal role in several clinical trials.

He has been on leadership position in many cancer organizations nationally and internationally. He is President of prestigious international organization FARO (Federation of Asian Organisations for Radiation Oncology) and was Board member of Gynecology Oncology, FIGO (Federation of Gynecology & Obstretics), an esteem international organisation. He has been the President of AROI (Association of Radiation Oncologists’ if India) between 2006-2008. He is also on the Scientific Advisory Committees of various leading institutions such as in Department of Atomic Energy (SARCAR committee), Mumbai, Rajiv Gandhi Cancer Institute, New Delhi. He is also Chairman of Institutional Ethics Committee (IEC) and has been the Chief Vigilence Officer (CVO) of Tata Memorial Center.

Dr Shrivastava is a member of numerous professional bodies in the country and abroad. He is receipient of several awards and honours.

Dr Shyam has over 250 peer reviewed publications, and chapters to his name. He is a member of the Editorial Board of Oncology international journals and is a reviewer for several scientific journals both national and international.

Dr Shrivastava has been examiner for post-graduate courses in several Universities in India and other countries like Sri Lanka, Indonesia, Nepal etc. His students are successfully working in India and abroad and receiving accolades for their achivements.

Hitoshi Ishikawa

QST Hospital, National Institutes for Quantum and Radiological Science and Technology

Position: Deputy Hospital Director
QST Hospital, National Institutes for Quantum and Radiological Science

EDUCATION
1995 - M.D., Gunma University, School of Medicine, Gunma, Japan
2002 - Ph.D., Gunma University, Graduate School of Medicine, Gunma, Japan

FACULTY APPOINTMENT 2002-2004 - Research Associate, Department of Radiation Oncology,
Gunma University, School of Medicine.
2004-2006 - Head Physician, Research Center for Charged Particle Therapy,
National Institute of Radiological Sciences (NIRS).
2006-2011 - Assistant Professor for Department of Radiation Oncology,
Gunma University, School of Medicine.
2011-2017 - Associate Professor of Department of Radiation Oncology, University
of Tsukuba, Faculty of Medicine
2017-2020 - Professor, Department of Radiation Oncology, University of Tsukuba,
Faculty of Medicine
2020-Present - Current position

AWARD
2007 - Research Encouragement Award,
International Association for the Sensitization of Cancer Treatment
2009 - Umegaki Award, Japanese Society for Radiation Oncology (JASTRO)
2009 - Research Encouragement Award, Kitakanto Medical Society
2013 - Excellent Presentation Award from Japan Society of Clinical Oncology
2016 - Award for Best Educational Lecturer, Japanese Society for Radiation Oncology
2020 - Abe Award, Japanese Society for Radiation Oncology (JASTRO)

Activity
#Councilors of JASTRO (2010-present), Japanese Lung Cancer Society (2013-present), Japanese Esophageal Society (2015), Japanese Society of Thermal Medicine (2017)
#Directors of Japanese Society of Thermal Medicine (2019-), Radiation Biology Group of JASTRO (2017-), International Association for Sensitization of Cancer Treatment (2019-)
#Member of Guideline Committee (JASTRO, Japanese Lung Cancer Society, Japanese Esophageal Society, Japanese Urological Association, Japanese Society of Thermal Medicine)

SKILL
IMRT, Brachytherapy, Proton Therapy, Carbon-ion Therapy, Hyperthermia, BNCT

Charlotte Coles

University of Cambridge

Charlotte Coles is Professor of Breast Cancer Clinical Oncology and Deputy Head of Department of Oncology, University of Cambridge. Her research aims are to provide breast cancer patients with the best chance of cure with least side effects by personalising radiation techniques based on risk of recurrence. She is Chief Investigator of 4 clinical trials with linked translational research:


1. IMPORT LOW: phase III randomised trial (RCT) investigating intensity modulated radiotherapy (IMRT) and partial breast radiotherapy in patients at low risk of recurrence – in follow up: 2018 patients recruited; 71 UK centres
2. IMPORT HIGH: phase III RCT investigating dose-escalated IMRT for patients at higher risk of recurrence - in follow up: 2617 patients recruited; 77 UK centres
3. PRIMETIME: prospective cohort investigating post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers – open: 50+ UK centres to date
4. NEO-RT: feasibility study investigating pre-operative breast IMRT in patients receiving neo-adjuvant hormonal treatment – open: 3 UK centres

Charlotte Coles is lead for Cancer Research UK Radnet-Cambridge Radiation Research Centre of Excellence:
https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/radnet-our-radiation-research-network

She a National Institute of Health Research (NIHR) Research Professor focussing on risk-adapted breast radiation therapy:
https://www.nihr.ac.uk/documents/current-nihr-research-professors/21758

She also Editor-in-Chief of Clinical Oncology journal:
https://www.journals.elsevier.com/clinical-oncology

Santam Chakraborty

Tata Medical Center

Consultant Radiation Oncologist at Tata Medical Center specializing in Breast, Gynecological Cancers and Sarcoma.

Manoj Gupta

AIIMS, Rishikesh

Qualifications MBBS, MD, DNB, MNAMS
Designation Dean, AIIMS, Rishikesh
Senior Professor & Head
Department of Radiation Oncology
Institute AIIMS, Rishikesh
Area of Interest Head and Neck Cancer, Breast Cancer, Clinical Radiobiology.




Awards
1. Nargis Dutt Memorial International Fellowship in 1998.
2. UICC Fellowship in 2004.
3. American Cancer Society Scholarship in 2006.
4. European Cancer Society Educational Award in 2007.
5. AROI-Dr Reddy International Fellowship in 2009.
6. AROI-Kirlosker International Fellowship in 2013.
7. Best Paper Award in National AROI Conference in 1993.

Publications - 110

Academic Contribution -Clinical Radiobiology Teaching Course

Bhavana Rai

Post graduate Institute of Medical Education and Research

Professor,Department of Radiotherapy and Oncology
Regional Cancer Centre, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh

Areas of Interest: Treatment of Gynecologic cancers, Gynecology brachytherapy, Palliative care

Fellowships and awards: Research projects (ongoing) Intramural Publications: 79

Chapter in Book: Ghoshal S, Rai B, Mrinyala R. Abdominal and Pelvic malignancies. In: Handbook of palliative Radiation. Candice Johnstone and Stephen T. Lutz (eds), Springer, New York, USA 2016. Pages 147-164.

Kristoffer Petersson

 University of Oxford

Bradford Hoppe

Mayo Clinic Florida

Bradford Hoppe, M.D., MPH, is a Professor of Radiation Oncology at Mayo Clinic Florida. He graduated from Cornell University Medical College and went on to do his training in radiation oncology at Memorial Sloan Kettering Cancer Center in NYC. Following residency, Dr. Hoppe worked at University of Florida for 11 years, where he was the James Lockwood endowed Professor of Proton therapy. In 2019, he was recruited by Mayo Clinic to be the Particle Therapy Medical Director.

Dr. Hoppe specializes in using particle therapy for the management of lymphoma, lung cancer, and prostate cancer. His research has focused on improving the therapeutic ratio with proton therapy for these malignancies. He is chair of the PTCOG lymphoma subcommittee, secretary of PTCOG-NA, ILROG steering committee member, Radiation Oncology lead for the COG pediatric Hodgkin lymphoma subcommittee, and ABR examiner for lymphoma.

Thomas DeLaney

Massachusetts General Hospital, Harvard Medical School

Thomas F. DeLaney, M.D. is a graduate of Harvard College and Medical School. Following internship in General Surgery at Yale-New Haven Hospital, he trained in Radiation Oncology at the Massachusetts General Hospital (MGH) followed by 6 years as a Senior Investigator at the NCI. Since 1992, he has been on the staff/faculty at MGH and Harvard Medical School (HMS). Currently, he is Associate Medical Director of the Burr Proton Therapy Center at MGH, Co-Director of the Sarcoma Center at MGH, and Andres Soriano Professor of Radiation Oncology (HMS). He is a Fellow of the American Society for Radiation Oncology (ASTRO).

He has served on the Executive Board of the Connective Tissue Oncology Society and the NCCN Soft Tissue Sarcoma Guidelines Panel, and currently serves as a member of the Medical Advisory Board of the Chordoma Foundation. He leads the NRG Oncology Proton Clinical Trials Working Group and is an active member of the NRG Oncology Sarcoma Working Group.

Dr. DeLaney is active in sarcoma and proton radiation clinical research. He was the principal investigator of NCI-funded P01 and U19 proton therapy grants from 2005-2016. His curriculum vitae lists over 170 original reports as well as over 100 reviews, book chapters, editorials, and clinical guidelines. He co-edited the books, Proton and Charged Particle Radiotherapy (2007) and Sarcomas: Evidence-Based Diagnosis and Management (2020) . He has served on the editorial boards of the Journal of Surgical Oncology, Annals of Surgical Oncology, Journal of Clinical Oncology, and UpToDate in Oncology.

Sarbani Laskar

D.M.R.T., M.D. in Radiation Oncology, D.N.B., Tata Memorial Centre

Dr. Sarbani Ghosh Laskar is A professor of Radiation Oncology from the Tata Memorial Centre, Mumbai, India. Trained and practicing Radiation Oncology at the TMC. Expertise lies in the multimodality treatment of Head and Neck and Esophageal malignancies. Has a keen interest in the treatment of these cancers with particular expertise in precision EBRT techniques, brachytherapy. Has participated in several investigators initiated and industry supported trials in these areas and has several publications in peer reviewed journals. Has also served 10 years in the Data monitoring and Safety Sub Committee of the Ethics in the Institute with 4 of these as the Secretary of the Committee and member of the IEC. Has been a teacher for MD (Radiotherapy) since 2009.

Vedang Murthy

Professor of Radiation Oncology ,MD, DNB, DipEPP, Tata Memorial Centre

Prof. Vedang Murthy, MD, DNB, DipEPP, is a Professor and Radiation Oncologist at Tata Memorial Centre, Mumbai, a premier oncology centre in Asia. Dr Murthy's area of expertise is in Urological Cancer. He has special interest in high precision radiotherapy procedures such as Image Guided Radiotherapy and Adaptive Radiotherapy. Dr. Murthy did his training in the field of Radiation Oncology from Tata Memorial Hospital in 2002 before going to the United Kingdom where he worked at The Royal Marsden NHS Foundation Hospital, London for a period of 4 years in the Academic Radiotherapy Unit. He also undertook a Diploma in Epidemiology and Biostatistics from the London School of Health and Tropical Medicine. He has several publications in peer reviewed international journals. Dr Murthy is currently running several investigators initiated clinical trials including randomised controlled trials in prostate and bladder cancer and is a part of international co-operative groups in GU Oncology. The main areas of interest within GU oncology are high risk prostate cancer, SBRT for prostate and kidney cancer, oligometastatic prostate cancer, bladder preservation and adjuvant radiotherapy in bladder cancer.

Reena Engineer

Professor of Radiation Oncology , DMRT, MD, DNB , Tata Memorial Centre

Dr. Reena Engineer is A professor of Radiation Oncology from the Tata Memorial Centre, Mumbai, India. Trained and practicing Radiation Oncology at the TMC. Has a keen interest in the treatment of these cancers with particular expertise in Gastrointestinal and Gynecological malignancies, Chronic Myeloid Leukemia (CML), Stomach and Small Intestine Cancer, Cardiac MRI (Magnetic Resonance Imaging) Of Heart Or Chest. Has participated in several investigators initiated and industry supported trials in these areas and has several publications in peer reviewed journals.

Shyam Shrivastava

Professor of  Radiation Oncology

Medical Qualifications MBBS in 1977; MD (Radiotherapy) in 1981 from Indore University and DNB (Radiotherapy) of National Board, Delhi in 1984.

Torunn Yock

MD MCH FASTRO -Massachusetts General Hospital Department of Radiation Oncology Professor, Harvard Medical School Director, Pediatric Radiation Oncology

Professor Torunn Yock has an MD from Harvard Medical School (HMS) and obtained a Masters of Community Health from the University of New South Wales in Sydney Australia as a Fulbright Scholar. After completing Radiation Oncology Residency at Massachusetts General Hospital (HMS affiliated hospital) she was hired on in 2003 as an Instructor in Radiation Oncology and rose through the ranks to Professor in 2019. She is the Director of Pediatric Radiation Oncology and Chair of the Quality Improvement Committee in Radiation Oncology and holds numerous leadership positions and serves on multiple committees locally and nationally for various societies including Children’s Oncology Group (COG) the American Society of Therapeutic Radiation Oncology (ASTRO), the American Board of Radiology, Proton Collaborative Group (PCG), and the National Association of Proton Therapy (NAPT). She was honored in 2019 by election as a Fellow of ASTRO. She is a pioneer in proton radiotherapy for pediatric patients and a recognized international expert in developing patient registries. Dr. Yock’s life work has led to proton radiotherapy now being accepted as the gold standard of care for pediatric brain tumor and pediatric sarcoma patients across the United States, in Europe and Asia by documenting improved outcomes compared with photon techniques. Dr. Yock recognized the power of aggregated data in rare tumors and successfully established and grew the first comprehensive multi-institutional pediatric radiation oncology patient data base, the Pediatric Proton/Photon Consortium Registry (PPCR). She has co-authored over 150 articles and chapters and taught/mentored over 120 residents, fellows, and post-docs over her career. Dr. Yock also serves on the Advisory Board for the Massachusetts Cancer/SEER Registry and serves as a contributor and advisor to the National Childhood Cancer Registry (NCCR) and the Childhood Cancer Data Initiative (CCDI). Her registry expertise is sought out by the NCI, who is contracting with her in 3 separate studies leveraging the power of her patient registries. She is known for her collaborative spirit and eagerness to work with others for the greater good of patients.

Eugen Hug

Medical Director and Co-Managing Director
at the MedAustron Ion Therapy Center in Wiener Neustadt

Professor Dr. Eugen Hug holds the position of Medical Director and Co-Managing Director at the MedAustron Ion Therapy Center in Wiener Neustadt, Austria. Since the early 90s and following completion of his residency in Radiation Oncology at Massachusetts General Hospital, he pioneered the introduction of Particle Therapy for various diseases intoroutine clinical practice. Amongst others, he held senior positions as the Director of the Paul Scherrer Proton Institute in Switzerland, Professor at the Universityof Zurich, Professor of Radiation Oncology and Pediatrics at Dartmouth Medical School as well as CMO at ProCure of four proton centers in the USA. His clinical specialization focuses on pediatric malignancies, skull base tumors and sarcomas. He served as President of the Particle Therapy Cooperative Group (PTCOG) and isFounder and Past-President of PTCOG North America.He hasauthored numerous publications, founded worldwide seminars and teaches extensively on Particle Therapy.

Eugen Hug

Medical Director and Co-Managing Director
at the MedAustron Ion Therapy Center in Wiener Neustadt

Professor Dr. Eugen Hug holds the position of Medical Director and Co-Managing Director at the MedAustron Ion Therapy Center in Wiener Neustadt, Austria. Since the early 90s and following completion of his residency in Radiation Oncology at Massachusetts General Hospital, he pioneered the introduction of Particle Therapy for various diseases intoroutine clinical practice. Amongst others, he held senior positions as the Director of the Paul Scherrer Proton Institute in Switzerland, Professor at the Universityof Zurich, Professor of Radiation Oncology and Pediatrics at Dartmouth Medical School as well as CMO at ProCure of four proton centers in the USA. His clinical specialization focuses on pediatric malignancies, skull base tumors and sarcomas. He served as President of the Particle Therapy Cooperative Group (PTCOG) and isFounder and Past-President of PTCOG North America.He hasauthored numerous publications, founded worldwide seminars and teaches extensively on Particle Therapy.

Suresh Sharma

Department of Radiotherapy,
MM Institute of Medical Sciences and Research

Degree/ Diploma/ Fellowship : M.D. ( Radiotherapy ) Current Designation/ Position/Assignment : Professor Emeritus , Department of Radiotherapy
MM Institute of Medical Sciences and Research, Mullana, Ambala
Past Designation/ Position/ Assignment :

Indranil Mallick

Senior Consultant, Department of Radiation Oncology,
Tata Medical Center, Kolkata

Dr Indranil Mallick is a Senior Consultant in Radiation Oncology at Tata Medical Center, Kolkata. He obtained his MD degree in Radiotherapy from the Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh and completed further specialist training at the Tata Memorial Centre, Mumbai and at the Princess Margaret Hospital, University of Toronto.

His clinical interests are in genitourinary, gastrointestinal and head and neck cancers. He has been responsible for setting up clinical services in these cancers in Tata Medical Center, Kolkata and the commissioning and standardization of image-guided radiation therapy (IGRT). His research interests involve the application of conformal and intensity modulated radiation therapy (IMRT) and IGRT and hypofractionated protocols in prostate and head and neck cancer. He also has a keen interest in the implementation of e-learning programs, having led three important projects on IGRT, radiological anatomy for target volume delineation and the National Cancer Grid e-learning portal. He also has an interest in application of machine learning and artificial intelligence in oncology.

Jai Prakash Agarwal

M.D., D.M.R.T, Professor and Head of Department of Radiation Oncology, Tata Memorial Centre.

Dr. Jai Prakash Agarwal is Head and Professor of Radiation Oncology from the Tata Memorial Centre, Mumbai, India. Trained and practicing Radiation Oncology at the TMC for more than two decades. Expertise lies in the multimodality treatment of Head and Neck, Thoracic malignancies and Interstitial brachytherapy and intensity-modulated radiation therapy. Clinical and basic research at National and International i.e. IAEA/DST/Pharmaceutical Company etc. participated invarious phase I/II/III trails, multicentric trial on Head & Neck cancer, Cervix Cancer, Esophagous& Lung Cancer,published in Scientific Peer renewed National & International Journals.

Rajiv Sarin

MD, DNB, FRCR Professor Radiation Oncology, In-Charge Cancer Genetics Unit

Prof. Rajiv Sarin trained in Clinical Oncology & Radiation Oncology at the Tata Memorial Hospital (TMH) & the Royal Marsden Hospital London and Cancer Genetics at University of Utah, Salt Lake City. He is the lead investigator in Breast Cancer & Brain Tumour Radiotherapy & Cancer Genetics at TMH. Starting from the 1st registry of Hereditary Cancer in the country in 1996, he developed a model Cancer Genetics Unit comprising of a Cancer Genetics Clinic in 2003 & Genetics Lab (SARIN Lab) in 2007. Prof. Sarin is the lead investigator in the International Cancer Genome Consortium (ICGC) India project for Oral Cancers and also the ICMR Centre for Advanced Research in Cancer Genetics & Genomics. He serves as the member of two International working groups of the ICGC.

Prof. Sarin is a member of various expert committees & task forces for cancer research and cancer management & he drafted the base paper for research in the Indian National Cancer Control Programme. He is the Executive Editor of the Journal of Cancer Research & Therapeutics which is the leading Indexed Cancer Journal from developing World. He is also serves on the Editorial board of leading cancer journals like Lancet Oncology, Molecular Oncology, Radiotherapy Oncology, Cancer Biomarkers, Mammology etc. Has over 75 peer reviewed publications and editorials in leading journals on various issues of cancer, health care, Cancer genetics, radiobiology etc

Siddhartha Laskar

Professor of Radiation Oncology

Dr. Laskar currently works as a Professor of Radiation Oncology and Deputy Director, Academics at the Tata Memorial Centre, Mumbai. He specializes in the management of Pediatric, Hematolymphoid, Musculoskeletal malignancies with special interest in Interstitial Brachytherapy for Adults & Children, Complex External Beam Radiotherapy Techniques, Total Body Irradiation for BMT & Magna Field Irradiation, Extracranialstereotaxy. He has many peer reviewed publications and editorials in leading journals.

Tejpal Gupta

Professor, Radiation Oncology

Dr. Tejpal Gupta is currently Department of Radiation Oncology, Tata Memorial Centre, Mumbai, continuing research in the specialized scientific area of Tomotherapy. Tejpal Gupta is serving as an honorary reviewer for reputed journals and has authored several articles along with chapters in different books related to Helical Tomotherapy Based Image-Guided Intensity-Modulated Radiation Therapy for Complex, Irregular, Residual, Recurrent, Progressive Benign/ Low-Grade Meningiomas. Professor, Radiation Oncology, Officer-in-Charge, Epidemilogy and Clinical Trials Unit, Convener, Neuro-Oncology Disease Management Group, Tata Memorial Centre, Mumbai. He is also an Examiner of Radiotherapy Technologists Training Program, MSBTE, Mumbai.

Dr. Gupta received the International Education & Development Award of ASCO in 2006 and Puranik& Pradhan International (Overseas) Fellowship of AROI in 2007. He is the life or tenure member of several prestigious oncology societies, such as Association of the Radiation Oncologists of India (AROI), Indian Society of Neuro-Oncology (ISNO), Indian Association of Cancer Research (LACR), American Society of Clinical Oncology (ASCO) and so on. Dr. Gupta is board certified by several leading international and national journals. His research program focuses on Neuro-Oncology and Head-Neck Cancers. He has published over 120 publications in indexed medical literature.

Harald Paganetti

Massachusetts General Hospital and Harvard Medical School

Harald Paganetti isa Professor of Radiation Oncology at Harvard Medical School and Director of Physics Research for the Department of Radiation Oncology at Massachusetts General Hospital. He received his PhD in experimental nuclear physics in 1992 from the Rheinische-Friedrich-Wilhelms University in Bonn, Germany. Hehas been working in radiation therapy research since 1994 and hasmade many significant contributions to the field of radiation oncology physics and biology.He haspublished more than 250 peer-reviewed publications and various book chapters and edited 3 books on proton radiation therapy. His main research interests include all aspects of planning and delivery uncertainties in radiation therapy, including biological effect modeling, Monte Carlo dose calculation, as well as advanced optimization and imaging techniques.His current work specifically focuses on optimizing systemic effect of radiation treatments to increase the biological efficacy of radiation therapy.In addition to his research, he serves on editorial boards and is a member of task-groups and committees for various associations such as the National Council on Radiation Protection and Measurements (NCRP)and the American Society for Therapeutic Radiology and Oncology (ASTRO).

Shaista Hafeez

The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research

Dr Shaista Hafeez is a Clinician Scientist at The Institute of Cancer Research and Consultant Clinical Oncologistat The Royal Marsden NHS Foundation Trust, working in the Division of Radiotherapy and Imaging.

Dr Hafeez graduated from Imperial College School of Medicine and completed specialist clinical oncology training in London. In 2013 she was awarded a Cancer Research UK PhD Fellowship and undertook a period of research at The Institute of Cancer Research and The Royal Marsden Hospital investigating functional magnetic resonance imaging (MRI) and advanced image guided adaptive radiotherapy techniques in bladder cancer.

Dr Hafeez specialises in the radiotherapy and systemic treatment of patients with urological cancers. Her on-going research aims to improve patient outcomes by developing individualised approaches to radiotherapywith particular emphasis on the role ofMRI to inform both geometric and biological adaption of treatment through pipeline of research. Her work has received several awards including The Royal College of Radiologists Ross Award, The National Cancer Research Institute (NCRI) Prize, and in 2017 she was awarded The Chairman’s Prize, for her PhD at The Institute of Cancer Research.

Dr Hafeez currently leads the Bladder Group withinthe International MR Linac Consortium which is aglobalcollaborative group to develop evidence base for MR-guided radiotherapy. She is also ESTRO faculty teaching on the annual physics for modern radiotherapy course and NCRI Clinical and Translational Radiotherapy Research Working Group (CTRad) workstream memberwith focus on developing clinical radiotherapy researchrelatingtonew technologiesand functional imagingin order to help develop the next generation of radiotherapy trials.

Nidhi Patni

Bhagwan Mahaveer Cancer Hospital

Dr Nidhi Patni M.D.(Tata Memorial Hospital), D.N.B. Director and Consultant,
Radiation Oncology. Had established the department in 1997 in the only comprehensive cancer set up in the state of Rajasthan. Has been instrumental in promoting evidence based medicine in the state since then. Guide to DNB students since 2004. Special interest in CNS, breast and prostatic malignancies.

Dattatraya Muzumdar

Seth G.S. Medical College and King Edward VII Memorial hospital

Dr. Dattatraya Muzumdar is Professor of Neurosurgery at the Seth G.S. Medical College and King Edward VII Memorial hospital.
He has teaching experience of 21 years and has authored over 170 peer-reviewed publications including book chapters.
Founder member of the Indian Society of Neurooncology (ISNO) and served as its Secretary from 2009-2017.
Founder Editor in chief of International Journal of Neurooncology (IJNO), official journal of the Indian Society of Neurooncology (ISNO).
Editorial board membership: Journal of Neurooncology, Neurosurgical review, Pediatric Neurosurgery
Section editor, Neuro-oncology: Turkish Neurosurgery
He has been on the Editorial board member of ‘Indian Journal of Cancer’, official journal of the Indian Cancer Society, Indian Cooperative Oncology Network and Indian Society of Oncology
Contributor for ISNO national consensus guidelines on contemporary management of ‘Medulloblastoma’ and ‘Diffuse Gliomas’, published in Neurology India)
Basic research publications on Glioma –endothelial cell niche interactions in collaboration with the National Cell Sciences Centre (NCCS), Pune, Maharashtra, India
Collaboration with the Head Neck surgery division of Tata Memorial hospital to set up the Skull base surgery service (1999-2006)
Founder member of Joint Neurooncology meetings / Tumor board, established between KEM hospital and Tata Memorial hospital in 1999

Pranshu Mohindra

University of Maryland School of Medicine and Maryland Proton Treatment Center

• Associate Professor of Radiation Oncology University of Maryland School of Medicine (UMSOM) • Clinic Affiliation: University of Maryland Medical Center (UMMC) and Maryland Proton Treatment Center (MPTC), Baltimore, Maryland • Director of Billing and Compliance, Department of Radiation Oncology • Lead, Scope of Practice, Policy and Procedure Management Workgroup of Quality and Safety Review Council, Department of Radiation Oncology • Medical Student Elective Course Director, Department of Radiation Oncology • Director of Research Internships, Department of Radiation Oncology

Dr. Mohindra is an Associate Professor of Radiation Oncology at the University of Maryland School of Medicine, Baltimore (UMSOM). His prior training experience includes radiation oncology residencies (Tata Memorial Centre, Mumbai and University of Wisconsin, Madison), Head-Neck cancer clinical fellowship (Princess Margaret Hospital, University of Toronto) and a post-doctoral Global Academic Research Associate at the U. T. MD Anderson Cancer Center, Houston. His primary area of clinical and research interest is in thoracic/lung, gynecological and hemato-lymphoid malignancies.

His research efforts include evaluating treatment outcomes through institutional and population-based databases, development of early phase clinical trials evaluating both radiation sensitizers and radiation toxicity mitigators or evaluation of modern radiation techniques including proton beam therapy for the management of thoracic/lung, gynecological and hemato-lymphoid malignancies. He serves as national PI of two NCI-sponsored multi-institutional phase-I clinical trials (NCT02589522 and NCT02993146), Radiation Oncology Co-chair for the A041501A study and Alliance Champion for the NRG-sponsored national study: LU002.

His national leadership roles include Member Executive Committee and Member Board of Directors of the Alliance for Clinical Trials in Oncology, Vice-chair of the International Committee and Co-chair the International Observership Task Group of the American Brachytherapy Society and Vice-chair of the Workforce Sub-Committee of American Society for Radiation Oncology. Dr. Mohindra directs the Annual University of Maryland Mock Orals Course in Radiation Oncology to help young attendings prepare for Board Certification Exams and chairs the thoracic section of the ACR Radiation Oncology In-Training (TXITTM) Exam.

Danny Vesprini

Sunnybrook Health Sciences Centre

Dr Danny Vesprini is a Radiation Oncologist specializing in Prostateand BreastCancer at the Sunnybrook Odette Cancer Centre, Affiliate Scientist at the Sunnybrook Research Institute and an Assistant Professor at the University of Toronto.He is one of the Principle Investigators of the Sunnybrook Active Surveillance Program, the Director of the Male Oncology Research and Education (MORE) program which focuses on men that have developed or are at a high risk of developing aggressive prostate cancer.He is also the Principle Investigator of several ongoing clinical trials with one of his foci being the integration of new technologies into prostate cancer treatment including real-time MR guided stereotactic ablative body radiotherapy (MR-SABR), as well as ablative radiotherapy as definitive therapy for breast cancer in women who are not surgical candidates.

Remi Nout

Erasmus Mc Cancer Institute, University Medical Center Rotterdam, Department of Radiotherapy

Remi Nout currently heads the department of Radiation Oncology of the Erasmus Medical Center, Rotterdam, the Netherlands. As clinician his special interests are the treatment of gynaecological cancers. As researcher he is involved in the PORTEC study group in endometrial cancer, and the EMBRACE studies for cervical cancer. He was awarded with a clinical fellowship of the Dutch Cancer Society. He is past radiation representative in the council of the International Society of Gynaecological Cancer (IGCS), is treasurer and chair elect of the Dutch Gynaecological Oncology Group and is chair of the Dutch Platform for Radiotherapy of Gynaecological Malignancies. He is co-course director of the ESTRO Gyn course. As ESTRO representative has been involved in recent multidisciplinary European Guidelines for endometrial cancer (ESGO-ESMO-ESTRO) and cervical cancer (ESGO-ESTRO-ESP).

Apurba Kalita

Dr B Borooah Cancer Institute, Guwahati

Professor and Head,
Dept. of Radiation Oncology
Dr B Borooah Cancer Institute, Guwahati
MBBS - Jan 1985 - Gauhati Medical College, Gauhati – Gauhati University.
DMRD - May/June 1989 – Assam Medical College, Dibrugarh – Dibrugarh University.
DMRT – Jan 1996 – Tata Memorial Hospital, Mumbai – Bombay University.
MD (Radiotherapy) – Jan 1997 – Tata Memorial Hospital, Mumbai – Bombay University.
Publications 20 nos. of research publication in various indexed journals

Satyajit Pradhan

Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi-221005

Director, MPMMCC & HBCH Mar. 8, 2019- Continuing

AWARDS, RECOGNITION & HONOURS: FELLOWSHIPS AND SCHOLARSHIPS:

1. AROI-Kirloskar Therapeutics Fellowship. Tenable at MD Anderson Cancer Centre, Houston. 14.10.2014 to 31.10.2014.
2. UICC-ICRETT) Fellowship. Tenable at Royal Marsden Hospital, Sutton, UK. 16.11.2009 - 17.12.2009.
3. INSA-HAS (Hungarian Academy of Sciences) Bilateral Collaboration and Scientific Exchange Program Fellowship. Tenable at National Institute of Oncology, Budapest, Hungary. 17.08.09 - 09.09.09.
4. AROI-Novartis Fellowship. Availed at Long Beach Memorial Med. Ctr., CA, USA. 1.06.09- 27.06.09.
5. DST-SERC Visiting Fellowship-1998-1999. Tenable at CCMB, Hyderabad. 15.06.2000 - 11.09.2000.
6. UICC - ICRETT Fellowship. Tenable at Royal Marsden Hospital, Sutton, UK. 20.09.1999 - 29.10.1999.
7. Commonwealth Scholarship. Tenable at Institute of Cancer Research, Sutton, UK. 21.10.1997 - 20.10.1998.
8. Senior College Merit Scholarship. Government of State of Odisha. June 1979 - May 1981.


B) OFFICE BEARER OF SCIENTIFIC SOCIETIES: Chairman, Indian College of Radiation Oncology. 2018-2020.

Nagraj Huilgol

Head of Radiation Oncology

Dr. Nagraj G. Huilgol was trained in Obstetrics and Gynaecology and finished his MD from All India Institute of Medical Sciences. He has been the editor of JCRT and currently edits JRCR. Is also a founding editor for, ‘A repository of reflections in Philosophy Science and Gaming. It is a digital journal to disseminate creative writing in Science.

Kaustav Talapatra

Kokilaben Dhirubhai Ambani Hospital

1. Current designation : National Head, Radiation Oncology Kokilaben Dhirubhai Ambani Hospital, Mumbai and Reliance Cancer Hospitals, India

Previous Workplaces : • Tata Memorial Hospital, Mumbai
• Christian Medical College (CMC), Vellore.
2. Profile :
 Director : Varian Advanced International Clinical Stereotactic Radiosurgery.
 Joint Secretary : Association of Radiation Oncologists of India (AROI)
 Editor (Section) in Indian Journal of Medical and Paediatric Oncology (IJMPO)
 National Co-ordinator for 'The Best of ASTRO'
 Core Committee Member(CII)
 International and National Presentations more than 200
 Trained at :
• Christian Medical Colleg (CMC), Vellore
• Tata Memorial Hospital, Mumbai
 International Trainings :
• National Cancer Centre, Singapore
• High Precision / SRS Radiation Training
 Humanitas , Italy
 Champalimaud , Portugal
 Zug , Switzerland
Areas of Interest :
• Radiosurgery
• High Precision Radiation
• Sites – Gastrointestinal , Lung , Head & Neck
Publications :
36 ( in key Journals like International Journal of Radiation Oncology Biology Physics, Radiotherapy & Oncology, British Journal of Surgery, Journal of Cancer Research and Therapeutics and others)
Contributions :
• Played a pivotal role in bringing 'The Best of ASTRO' to India in 2015
• Played a pivotal role in setting up Cancer Hospitals I’m tier 2 and tier 3 cities of India like Akola, Gondhia and Sholapur
• Played a pivotal role in setting up a Stereotactic Radiosurgery School in Mumbai, India to train Radiation Oncology personnels.

Anusheel Munshi

Manipal Hospital

Head, Radiation Oncology, Manipal Hospitals, New Delhi

Dr. Anusheel Munshi is the Head of Radiation Oncology at Manipal Hospital, New Delhi. Dr. Munshi has worked at the most reputed centers in India, including the Tata Memorial Hospital Mumbai, All India Institute of Medical Sciences and PGIMER Chandigarh. He is a rank holder and a gold medalist from his academic days. He has over 150 international and national publications in peer reviewed journals to his credit and has authored several chapters in oncology books. Dr Munshi has conducted several trials in breast, brain and lung cancers, including investigator initiated trials.

Kannan Venkatesan

PD Hinduja National Hospital

M.B.B.S., M.D. (AIIMS)
Consultant and Head, Radiation Oncology, P.D. Hinduja National Hospital

First in India to start 3DCRT in 1998, IMRT in 2001 and 4D Gated radiotherapy in 2008.

Teaching faculty for MSc Diploma Radiation physics students, Mumbai
Reviewer for
1. Journal of cancer research and therapeutics (JCRT)
2. Editor - Journal of Radiation and Cancer Research
3. Editor - Indian journal of Cancer

Steering committee member of the project “Establishment of facility for batch fabrication of linear accelerator tubes and linear accelerator machine”, a project of Department of IT, Government of India.

Scientific Publications - International & National : 105
Invited lectures : > 100

Life member/foundation member of major oncology associations of AROI, ICRO , ISO, ASTRO

Rakesh Kapoor

Homi Bhabha Cancer Hospital and Research Centre Punjab

MD, MAMS, FICRO
HBCH & RC TMC MEDICITY New Chandigarh

Ex. Professor and Unit Head department of Radiation Oncology PGIMER , Chandigarh
Areas of Speciality:
Carcinoma of Lung
Carcinoma Breast
Gastrointestinal cancers
Bone Tumors and Sarcomas
Brachytherapy Techniques in various cancers pediatric Tumors
Epidemiological studies in Cancer
Palliative care

Ashwini Budrukkar

D.M.R.T., M.D., D.N.B., Professor, Radiation Oncology

Dr. Ashwini Budrukkar currently works as a Professor of Radiation Oncology at the Tata Memorial Centre, Mumbai. She specializes in the management of Head & Neck Malignancies, Breast Malignancies. Has a keen interest in the treatment of these cancers with particular expertise in precision EBRT techniques, brachytherapy. Has participated in several investigators initiated and industry supported trials in these areas and has several publications in peer reviewed journals

Supriya Chopra

MD, Professor Radiation Oncology

Presently working asProfessor of Radiation Oncology and specialize in Gynecology and Gastrointestinal Radiation Oncology. She has many peer reviewed publications and editorials in leading journals.At present I am serving as Principal Investigator and Co -Investigator trials in Gynecology and GI Radiation Oncology. Key interest areas involve evaluation of new technology and integrating functional imaging for response assessment in Gynecologyand GI cancers.Area of research in the field of Gynecology Image Guided Interstitial and Intracavitory Brachytherapy, SBRT for Liver and IMRT for postoperative pelvic irradiation.

Goda Jayant Sastri

Professor and Clinician Scientist, Radiation Oncology

Dr Jayant SastriGoda is aProfessor and clinician scientist in the department of Radiation Oncology at Tata Memorial Centre, Mumbai. His chief interests are in Hematolymphoid especially radiation therapy in low grade lymphomas and radiotherapy in the setting of haemopoetic stem cell transplant and Neuro oncology besides having special interests in new drug development and repositioning of drugs in the field of radiation modifiers.He has many peer reviewed publications and editorials in leading journals.

Nehal Khanna

MD, DNB, Professor of Radiation Oncologist

Dr. Nehal R Khanna is a Professor of Radiation Oncologist at Tata Memorial Centre, Mumbai, India. She is associated with Pediatric Oncology, Hemato-Lymphoid and Bone and Soft tissue disease management group. She has special interest in Sarcomas and Pediatric solid tumors. Her expertise lies in Brachytherapy procedures for sarcomas. She was the recipient of the ICON best project award in 2006 and IDEA ASCO fellowship award in 2011. She has multiple publications in peer reviewed journals. She is one of the few radiation oncologists in India with dedicated practice of treating patients with bone and soft tissue tumors.She has many peer reviewed publications and editorials in leading journals.

Rahul Krishnatry

Associate Professor of Radiation Oncology

Dr Rahul Krishnatry is an Associate Professor in the Department of Radiation Oncology from the Tata Memorial Centre, Mumbai, India. Trained from PGIMER, Chandigarh; Tata Memorial Centre, Mumbai; The Hospital for Sick Children and Princess Margret Cancer Centre, U of T, Canada and practising Radiation Oncology at the TMC for last 5 years. Expertise lies in the multimodality treatment of Brain tumours, Urological malignancies and GI tumours. He has a special interest in the development of Quality Care, Radiation Therapy Error and Safety Program, Radiation Oncology Information System development and Survivor and post-care clinic development. Clinical and basic research at National and International studies with more than 50 peer-reviewed articles. JM Pinto Gold Medal (2009), ASCO IDEA award (2012), International Research Development Award (Grant) by Society of Neuro-Oncology (2013) to name a few prominent awards other several best paper awards at national and international meetings and travel grants or fellowships.

Naveen Mummudi

Associate Professor of Radiation Oncology

MBBS, DMRT, MD Special interest: Thoracic malignancies, Head and neck cancer & Brachytherapy
Associate Professor,
Department of Radiation Oncology, Tata memorial Centre Mumbai - 400012

Lavanya G

Assistant Professor of Radiation Oncology

Dr. Lavanya G currently am working as Assistant Professor in the department of Radiation Oncology at Tata Memorial Hospital in Mumbai, India. She is a clinician with special interest in Gynecological malignancies including image guided brachytherapy. Shehas been working as member in the Gynecological disease management group at our Hospital. She has been actively participating in the ongoing institutional trials in our Institute.

Rima Pathak

MD ,Assistant Professor of Radiation Oncology

Dr. Rima Pathak currently am working as Assistant Professor in the department of Radiation Oncology at Tata Memorial Hospital in Mumbai, India. She is a clinician with special interest in Breast malignancies including image guided brachytherapy. She has been working as member in the Breast disease management group at our Hospital. She has been actively participating in the ongoing institutional trials in our Institute.

Debnarayan Dutta

Amrita Institute of Medical Science, Kochi

• Dr Debnarayan Dutta at present working as Associate Professor & Head of Amrita Institute of Medical Science, Kochi.
• He received his training from Tata Memorial Hospital, Mumbai as fellow and registrar. He has worked at Apollo Hospital, Chennai as consultant for 7 years.
• He has completed under-graduate training from National Medical College, Kolkata.
• He has 61 indexed publication, more than 50 indexed abstracts and author of three books. He is investigator of few ongoing clinical trials.
• He completed his PhD from VIT, Vellore in molecular prognostication of head & neck cancer.
• Apart from academics, he is involved in philanthropic work for under privileged cancer patients from Bengal. He is founder trustee of Bengal Cancer Foundation Charitable trust.
• He has travelled across different part of Eastern India and well aware of the practical situation regarding cancer patient treatment in this part of India.

Umesh Mahantshetty

Director, Homi Bhabha Cancer Hospital & Research Centre

DMRT, MD,DNB (RT) Director, Homi Bhabha Cancer Hospital & Research Centre,
( A Unit of Tata Memorial Centre, under Department of Atomic Energy, Govt. of India) Page 1Dr Umesh Mahantshetty, joined as Director of Homi Bhabha Cancer Hospital& Research Centre, Visakhapatnam-A Unit of Tata Memorial Centre, Mumbai, Indiasince April2020–was formerlyworking in Radiation Oncology at Tata Memorial Centre, Mumbai India-one of the largest comprehensive cancer center in Asiafor 16 years.After completion of MD and Senior Residency at Tata Memorial Hospital,has completed fellowships in brachytherapy and newer imaging at Erasmus Medical Centre, Rotterdam NL and MD AndersonCancer Center, Houston, USA.

Dr. Mahantshetty is specialized and highly recognized in the field of Gyecology Oncology and is one of the key opinion recognized leader globally inthe field of GYN Oncology including highprecision radiation techniques andImage Based Brachytherapy. His numerous achievements include Expert for establishing guidelinesat national (ICMR Guidelinesfor Cervical Cancer) and international (ESGO / ESTRO guidelines for vulvar and cervical cancer management) bodies, a consultant tothe recent ICRU 89 Report on GYN Brachytherapyand Senior Editor of various prestigious International and National Journals.

At presentleading the GYNRadiation Oncology group at Tata Memorial Hospital, he is involved numerous projects and research protocols which have high impact on both the developing and developed world.He has also been instrumental in building up the Indian Brachytherapy Society (IBS) in the capacity of Secretary since 2013and part of Executive Committees of Association of Radiation Oncologists of India (AROI) and GYN Oncologists of India (AGOI) since many years.

As an Invited speaker, he has delivered numerous lectures at various national and international scientific forumsand has been actively involved as faculty of ESTRO School for GYN Radiation Oncology and Advanced Technologies teaching courses, IAEA training Activitiesand is Director of AROI –ESTRO Coursein India.

Dr.Mahantshetty’s numerous research publications in high impact journals such as JAMA Oncology, Lancet Oncology, JCO,IJROBP, Radiotherapy Oncologyetc; have been instrumental in guiding treatmentphilosophies in the management of cervical cancers. In particular, his work on practice changing studies in cervical cancers, collaborative research with GYN ESTRO, UCSD groups,image based brachytherapyin cervical cancers, hasbeen keenly observed and acknowledged by researchers world-wide.Till date he has approximately 200original publications in peer reviewed journals and as text book chapters.

Dr Mahantshetty is also activelyinvolved in various green projects, TMC Cancer satellite centers(Varanasi, Visakhapatnam, Sangrur, Mullanpuretc.)right from conception to operational processes for Radiation Oncology Units. In summary, Dr Mahantshetty is an Internationally acclaimed Oncologist, well known in Radiation Oncology Community for his contribution in GYN Oncology and a responsible, dedicated,and a well knownleader in Oncology.Since 1stApril 2020,he has been appointed as Director of Homi Bhabha Cancer Hospital& Research Centre, Visakhapatnamwhich is A Unit ff Tata Memorial Hospitalunder Department of Atomic Energy Government of India.In January 2021,was privilegedto be labelled as “ WORLD EXPERT”by Expertscape (https://www.expertscape.com/ex/uterine+cervical+neoplasms-world-wide recognition of being intop0.1% scholars writingthe research work in the field of UterineNeoplasms in last 10 years (2010-2020).

Giri GV

Secretary AROI, Sri Shankara Cancer Hospital and Research Centre

DMRT, MD, DNB

Consultant Radiation oncologist Sri Shankara Cancer Hospital and Research Centre.

Rajesh A. Kinhikar

MD, Assistant Professor, Radiation Oncology

Professor & Head
Department of Medical Physics
Tata Memorial Centre,
Mumbai-400012, INDIA
• Peer reviewed scientific papers submitted to the following international and national journals:
> Biomedical Physics and Engineering Science (BPEX)
> Journal of Clinical Oncology (JCO)
> Journal of Applied Clinical Medical Physics (JACMP)
> Physics in Medicine and Biology (PMB)
> Australasian Journal of Physics Engineering and Science (APESM)
> Journal of Medical Physics (India) and
> Journal of Clinical Research and Therapeutics (JCRT)
• Life member of AMPI & AROI
• EC Member of AMPI (2009-2011) and Treasurer of AMPI (2011-2013)

Coordinator for Dosimetry Quality Audits for IAEA and IROC/RTOG.

Sylvia Ng

Sunnybrook Odette Cancer Centre, University of Toronto

Dr. Sylvia Ng is a Staff Radiation Oncologist at the Sunnybrook Odette Cancer Centre, Assistant Professor in the Department of Radiation Oncology at the University of Toronto, and Affiliate Scientist at the Sunnybrook Research Institute. Her clinical interests include pancreatic and hepatobiliary cancers, stereotactic body radiotherapy, and MR-guided radiotherapy. She is the pancreatic cancer MR-LINAC lead at the Sunnybrook Odette Cancer Centre. Her research expertise is in pancreatic cancer, tumor microenvironment, and molecular pharmacology. Dr. Ng has published in the areas of translational research, cancer biology, targeted therapy, drug development, and biomarkers in addition to clinical radiation oncology.

Kausik Bhattacharya

Director, HOD, Radiation Oncology - AIG Hospital

Kausik Bhattacharya is the Director and Head of Radiation Oncology Department, AIG Hospitals, Hyderabad, India. He completed his post-graduation in Radiation Oncology from Regional Cancer Center, Cuttack in 1999 and trained further in All India Institute of Medical Sciences and Safdarjung Hospital in New Delhi.

He is having more than 20 years of clinical experience in and is a teacher and examiner with the National Board. He is a keen in the field of Brain Tumors, Colorectal, Lungs and Head and Neck Tumors. Prior to his present assignment, he served in Tata Memorial Hospital Mumbai for three years and joined the postgraduate faculty in Regional Cancer Center, Cuttack. Subsequently he served as Senior Consultant in Apollo Cancer Institute Hyderabad for 13 years.

He did his training in Neuro-oncology from Charite University of Medicine, Berlin, Germany and Lung SABR in Sheffield, UK.

Arti Sarin

Radio diagnosis

waiting for info

Sunil Dutt Sharma

RPAD, BARC, Mumbai

Dr. Sunil Dutt Sharma is a Senior Scientist (Medical Physics) and Head, Medical Physics Section of Radiological Physics & Advisory Division (RP&AD), Bhabha Atomic Research Centre (BARC), Mumbai, India. He has more than 28 years of working experience in the field of medical physics and radiation safety. He is a faculty and PhD guide in the disciplines of physical & health sciences of Homi Bhabha National Institute (a deemed to be university), Mumbai, India and guided four candidates for their PhD Degrees. He is the Coordinator of prestigious Post MSc Diploma in Radiological Physics (DipRP) course and RSO (Medical)/RSO (NM)/RSO (DR) certification examinations. He is a well-known researcher, renowned teacher and popular guide for many medical physicists of India and abroad. He devised the modality for internship in medical physics and implemented it at national level one go. He is also credited for bringing out a harmonized syllabus and course modality for Master Degree in Medical Physics / Post MSc Diploma in Radiological/ Medical Physics. He has immensely contributed towards medical physics education and training in India and also contributing for continuous development of professional quality. As far as research activities are concerned, Dr. Sharma is involved with design and development of radiotherapy equipments and treatment accessories; dosimeters, phantoms, QA/QC tools and quality audit methods for advanced radiotherapy techniques. He is also involved in Medical advisory services and safety evaluations of radiation generating medical equipment. He has authored/co-authored 115 papers in peer reviewed high impact international journals and 170 abstracts in the proceedings of national/ international conferences. He has also delivered more than 80 invited lectures in various scientific forums. He is serving as Associate Editor of Journal of Medical Physics (a PubMed indexed international journal) and reviewer of many international journals. Dr. S. D. Sharma is recipient of various awards and honours such as Gold Medal in M. Sc. (Phys), ICTP TRIL Fellowship for one year; Dr. C. A. Jayachandran Oration Award, DAE Scientific and Technical Excellence Award for developing a multisource remote operating device; DAE Group Achievement Award for developing a secondary multileaf collimator (MLC) for Bhabhatron telecobalt unit; IARP Dr. A. K. Ganguly Felicitation Prize for meritorious work in medical physics and radiation safety; and ARTTI Gunila Bentel Oration Award. Dr. Sharma is the President of Association of Medical Physicists of India (AMPI) and he has served AMPI in other capacities (Treasurer, Secretary General, Convener of AMPI Trust) in the past. He has also served College of Medical Physics of India (CMPI) as its Secretary cum Treasurer and Chief Examiner. In fact, he is a founding member of CMPI (a scientific wing of AMPI which conducts competency certification of medical physicists in India). He is serving global medical physics community as members of IOMP Accreditation Board and AFOMP Education and Training Committee.

Simon Pavamani

Christian Medical College Vellore

Dr. Simon Pavamani is the Professor & Head of the Department of Radiation Oncology in Christian Medical College (CMC), Vellore. He undertook his undergraduate (MBBS) & postgraduate training (MD-Radiotherapy) in CMC, Vellore followed by fellowship training in Canada in Head & Neck Cancers at the Western University in London, Ontario, and Prostate and Gynaecologic Brachytherapy at the University of Calgary, Alberta.

Currently, he treats Head and Neck, Genitourinary, Thoracic & Upper Gastrointestinal Malignancies. His research interests include diffusion weighted imaging in Head & Neck and Esophageal malignancies. Research in Radiomics in Head & Neck Cancer is currently ongoing with a scientist with a major grant in the Department of Radiation Oncology. He has been a member of the Institutional Review Board & held the post of the Vice Principal for Postgraduates at the CMC Vellore.

Shwetabh Sinha

MD, Assistant Professor, Radiation Oncology

Assistant Professor, Radiation Oncology Head and Neck disease management group Tata Memorial Centre, Mumbai

Francis James

Regional Cancer Centre

Professor of Radiation Oncology,Regional Cancer Centre, Trivandrum-695011. India.

International Training
• Fellowship of Leeds University, UK . June- December 1992.
• Fellowship of Institute of Cancer Research, London and Honorary Senior Registrar in Uro - Oncology, Royal Marsden Hospital, Sutton ,UK . March 1996- February 1997.
• Clinical Research Fellowship of Institute of Cancer Research in Uro-oncology , Royal Marsden Hospital ,UK. February 2002-April 2003.

Suman Mallik

Consultant Radiation Oncologist

Clinical Director and Chief of Radiation Oncology (March 2011 to till date)
Narayana Superspeciality Hospital (formerly Westbank Hospital), Howrah, India
• Past appointments
• Fellow in Stereotactic Radiosurgery and SBRT program, Princess Margaret Hospital, Toronto, Canada(May 2012 to June 2012)
• Consultant Radiation Oncologist (August 2009 to Feb 2011)
Kokilaben Dhirubhai Ambani Hospital and Research Institute, Mumbai, India
• Senior Registrar (November 2006 to July 2009)
Department of Radiation Oncology, Tata Memorial Hospital (TMH), Mumbai, India.
• Senior resident ( August 2006 to October 2006)
Department of Radiotherapy, Medical College Hospital, Kolkata, India
• Junior Resident (Post Graduate Trainee)(May 2003 to April 2006)
Department of Radiotherapy, Medical College Hospital, Kolkata, India under University of Calcutta. For the degree of MD (Radiotherapy).
• Junior Resident (Post Graduate Trainee) (November 2002 to April 2003)
Department of Chest Medicine, R.G. Kar Medical College, Kolkata, India, under University of Calcutta.
• Medical Officer (June 2001 to October 2002)
Critical Care Unit, Department of Cardiology and Cardiothoracic Surgery, Anandalok Hospital, Salt Lake, Kolkata, India.

Srinivas Chilukuri

Apollo Proton Cancer Centre

1. Senior Consultant Radiation Oncologist and Clinical Lead for IT and Innovations in Oncology at at Apollo Proton Cancer Centre, Chennai from March 2018.
2. Unit lead of Pediatric, Genito-urinary and Thoracic Cancer Management Team
3. Consultant Medical Affairs, Varian Medical System from April 15th, 2017.
4. Chairman, Optimus Oncology Pvt. Ltd. from October Ist 2016.

Vikas Jagtap

Associate professor & Head, Neigrihms, shillong

TOTAL EXPERIENCE : MORE THAN 10 YRS
AREAS OF INTEREST: Head and neck , Breast,Cervical cancers
MAJOR ACHIEVEMENTS:(HONOURS)(AWARDS)(PUBLICATIONS)-
Secretary North East AROI ( North East Chapter -Associationof Radiation Oncologists of India)
-Editor Newsletter AROI
-Secretary Association of Oncologists of North East India (AONEI)
-AROI overseas fellowship 35-40 yrs
-National , International Publications

Shaleen Kumar

Director, Super Specialty Cancer Institute & Hospital

• MD, Radiotherapy, 1991, King Georges Medical College, Lucknow University, Lucknow, Uttar Pradesh, India -- Radiotherapy Professional Experience / Training:
• Director – April 2018 - present Super Specialty Cancer Institute & Hospital, CG City, Lucknow 226014 • Professor – (Jan 2007 & as Head, Oct 2007 – April 2018); Addl Prof (July 2004 – Dec 2006); Assoc Prof (July 2000 – June 2004); Asstt Prof (April 1996 – June 2000); Senior Research Associate - April 1995 – April 1996: Department of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India • Clinical Research Fellow – (Jan. 2002 – March 2003), Neuro-Oncology Unit, The Royal Marsden Hospital, Fulham Road, London, UK - (Commonwealth Fellow) • Senior Resident – Nov 1991 – March 1995, Department of Radiotherapy, Tata Memorial Hospital, Mumbai, India Activities: • Principal areas of research interest have been head-neck cancers, esophageal cancers, neuro-oncology, stereotactic conformal radiotherapy. Researcher, clinician and teacher. • Author or co-author of some 70 research articles and 5 book chapters in areas of clinical oncology and medical physics in peer reviewed medical journals.

Jifmi Jose Manjali

Assistant Professor

Department – Radiation Oncology
DMG – Padiatric Solid tumors and Bone- Soft tissue Tumors
Hospital – Tata Memorial Hospital, Mumbai

Ramesh S Bilimagga

Healthcare Global Enterprises

Prof. Ramesh S Bilimagga, is a qualified and trained Radiation Oncologist. He has completed his M.D. in Radiotherapy from Bangalore Medical College. He has received training in Nuclear Medicine from Bhabha Atomic Research Center, Mumbai. He has over 43 years of experience, in the field of Radiation Oncology.

He was a clinical observer in International Hospitals such as; Norfolk Medical School, Virginia, USA, UCLA, California, USA, Long Beach Memorial Hospital, USA, and Mount Sanai Hospital, Baltimore, USA. He is certified Cyber Knife Trained person by Accuracy from U.S.A. He is Fellow of International College of Surgeons (Indian Section) and Fellow of Indian College of Radiation Oncology. His special areas of interest are HDR brachytherapy, Chemo-Radiation and conformal radiotherapy in Head and Neck and Gynae-oncology.He is in the Editorial board of Journal of Cancer Research & Therapeutics India & Contemporary Brachytherapy of Polish Brachytherapy Society & JCRT, India.

He has received many awards for his work in the field of Radiation Oncology; some of them are Prof. P.K. Haldar Memorial Travel Fellowship and Travel Fellowship of International College of Surgeon and many more. He was the Chairman of ICRO (Indian College of Radiation Oncology) and the National President AROI (Association of Radiation Oncologist of INDIA) in 2010. President Elect for Indian Society of Oncology. President of Indian Association of Hyperthermic Oncology and Medicine. President of Consortium for Tobacco Free Karnataka His academic achievement are, was professor & HOD of Radiotherapy M.S. Ramaiah Medical College, affiliated to RGUHS, Bangalore. He is training post graduate students in DNBRadiation oncology. He has 36 publications in National and International Journals.He is the Senior Consultant in Radiation Oncology inHCG Group of hospitals

Rojymon Jacob

University of Alabama at Birmingham

I am Rojymon Jacob, Professor of Radiation Oncology at the University of Alabama (UAB), USA. Our Radiation Oncology department and training program are ranked among the best in US. I am the lead GI-Radiation Oncologist for our institution and an educator and mentor for the residency and medical graduate programs in our university. I serve the American Board of Radiology, NCCN and RTOG in various committees.

At this meeting, I will be talking on the subject of SBRT for Hepatocellular Cancer. I will give an overview of the global challenge posed by HCC and available options for its treatment. I will discuss the challenges we face while using Liver SBRT, and possible solutions. Finally, I will discuss the role of proton therapy and the promise it holds for treating HCC.

Thomas Merchant

St. Jude Childrens Research Hospital

Dr. Thomas E. Merchant is the Baddia J. Rashid Endowed Chair in Radiation Oncology at St. Jude Children’s Research Hospital in Memphis, Tennessee where he has practiced for more than 20 years. Prior to his appointment at St. Jude, he was a member of the medical staff in the Department of Radiation Oncology at the Memorial Sloan-Kettering Cancer Center in New York, New York. He was originally trained as a nuclear engineer at the University of Michigan. After completing his engineering degree, and prior to attending medical school at the Chicago College of Osteopathic Medicine, he worked in the area of radiation protection and safety for the French Atomic Energy Commission in Fontenay-aux-Roses, France. After medical school, he was a Fulbright Scholar to the Netherlands at the University of Utrecht where he received his PhD, cum laude, in experimental pathology. He interned at the Chicago Osteopathic Hospital and performed his residency at the Memorial Sloan-Kettering Cancer Center. As a part of his formal medical and residency training, he spent time at the Massachusetts Eye and Ear Infirmary in Boston and Curie Institute in Paris and was awarded an American College of Radiation Oncology Fellowship at the Joint Center for Radiation Therapy and Children’s Hospital Boston.

The subject of his research has been the application of advanced radiotherapy methods in the treatment of children with cancer. His focus has been in pediatric neuro-oncology where he developed new guidelines and designed new treatment methods for children with brain tumors and modeled radiation-related CNS effects. The broad long-term goal of his research has been to increase the cure rates for the most common brain tumors and reduce or eliminate the side effects of radiation therapy. In the Children’s Oncology Group, he served as the Chair of the Radiation Oncology Discipline and Vice-chair of the CNS Disease Committee from 2005-2015. He was the Principal Investigator for the most recently completed ependymoma study. Dr. Merchant’s current efforts include leading the development of new guidelines to research the role of intensity-modulated proton therapy in the treatment of children with brain and solid tumors. To that end, he completed a sabbatical at the Paul Scherrer Institute in Villigen, Switzerland, where he studied proton spot scanning. He then lead the development of the St. Jude Red Frog Events Proton Therapy Center that opened in 2015, the world’s first and only proton therapy center dedicated solely to the treatment of children with cancer.

Ido Bitan

Product Manager medical ,stratasys Israel